This Genome Sequencing Stock’s Monster Run May Be Far From Over

In the genome sequencing space, the stock highlighted in today’s article may not be the best stock – yet. As the author details, however, “when it comes to shareholder returns in the past year, [it] was one of the top performers, rewarding investors lavishly.” In fact, this biotechnology company, which develops gene sequencing systems, has seen its stock surge around 1700% over the past year – and its monster run may be set to continue. For more, CLICK HERE.